Overview
What is Global Alliance For Tb Drug Development Inc?
Global Alliance for TB Drug Development Inc, also known as TB Alliance, is a New York-based not-for-profit organization focused on expediting the discovery and development of new drugs to combat tuberculosis (TB) globally. TB Alliance builds partnerships amongst public, private, academic, and philanthropic sectors, retaining direct management oversight while outsourcing laboratory and clinical work. Their innovative business model minimizes costs and maximizes scientific capability to swiftly advance TB drug development. TB Alliance is currently conducting the SIMPLICITB study, evaluating a novel drug regimen named BPAMZ for drug-sensitive and drug-resistant pulmonary tuberculosis. Additionally, they have launched an access program called LIFT-TB to increase treatment completion rates for drug-resistant TB, and are making a promising clinical-stage drug candidate, Sutezolid, available for study by the broader TB research community. TB Alliance's mission is to develop better, faster-acting, and affordable TB drugs for those in need.
Official website here: www.tballiance.org
Is Global Alliance For Tb Drug Development Inc legitimate?
Global Alliance For Tb Drug Development Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. Global Alliance For Tb Drug Development Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $3,962,233
Professional Fundraising Fees: $0
Other Salaries and Wages: $9,281,300
For more financial information, click here
Official website here: www.tballiance.org
What is the mission statement of Global Alliance For Tb Drug Development Inc?
The Global Alliance for TB Drug Development Inc is a not-for-profit organization dedicated to the discovery, development, and delivery of better, faster-acting, and affordable tuberculosis (TB) drugs for the global community. They are uniquely positioned to efficiently advance TB drug development through partnerships between the public, private, academic, and philanthropic sectors. The organization retains management oversight of its projects while most laboratory and clinical work is carried out through external research facilities and contractors. By combining research and development expertise with partners' skills and resources, TB Alliance minimizes costs and optimizes scientific capability to speed new TB drug development. The organization's collaborative business model and diverse partnerships enable significant improvement in drug development efforts. They are currently evaluating the efficacy, safety, and tolerability of a novel drug regimen for drug-sensitive and drug-resistant pulmonary TB, and have made promising progress in reducing the dosing of Linezolid in the treatment of extensively drug-resistant TB. Their mission is to bring new and effective TB drugs to those who need them most.
Official website here: www.tballiance.org
Who is the CEO of Global Alliance For Tb Drug Development Inc?
Angela Vanderploeg is the President/Ceo of Global Alliance For Tb Drug Development Inc. The CEO's salary of Global Alliance For Tb Drug Development Inc is $908,988 and their total compensation is $1,009,857.
Official website here: www.tballiance.org
What is the revenue of Global Alliance For Tb Drug Development Inc?
Global Alliance For Tb Drug Development Inc's revenue in 2022 was $56,212,963.
Official website here: www.tballiance.org
Who are the executives of Global Alliance For Tb Drug Development Inc and what are their salaries?
The average compensation at Global Alliance For Tb Drug Development Inc during 2022 was $245,251. There are 54 employees and 13 volunteers at Global Alliance For Tb Drug Development Inc.
Here are 24 key members and their salaries (Global Alliance For Tb Drug Development Inc's CEO's salary is $908,988 and their total compensation is $1,009,857):
- Dr Melvin Spigelman (President/Ceo) [Trustee/Director]
- Dr Nader Fotouhi (Chief Scientific Officer)
- Dr Eugene Sun (Sr. Vp, Research & Dev'T)
- Colleen Pero (Secretary/Cao)
- Robert Lorette (Sr. Vp, Business Development)
- Angela Vanderploeg (Treasurer/Cfo)
- Kathleen Schostack (Sr. Vp, Prog. & Alliance Mgmt)
- Sandeep Juneja (Sr. Vp, Market Access)
- Dr Paul Bruinenberg (Sr. Medical Officer)
- Salah Foraida (Sr. Director, Medical Affairs)
- Maria Beumont (Vp, Chief Medical Officer)
- Pietro Turilli (Sr.Vp, Ext Aff(As Of 06/01/22))
- Dr Bruce Carter (Chairman) [Trustee/Director]
- Dr Mario Raviglione (Vice Chair) [Trustee/Director]
- Eric Goosby (Director)
- Jane Griffiths (Director)
- Rasha Hibri (Director (As Of 09/01/22))
- Sundar Kodiyalam (Director)
- David Norton (Director)
- Ariel Pablos-Mendez (Director)
- Sangita Reddy (Director (Thru 05/15/22))
- Kim Schwartz (Director (As Of 09/01/22))
- Shalini Sharp (Director)
- Mitchell Warren (Director)
Official website here: www.tballiance.org
Where can I find the form 990 for Global Alliance For Tb Drug Development Inc?
The Global Alliance For Tb Drug Development Inc’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.tballiance.org
Learn more at the official website: www.tballiance.org
Mission Statement of Global Alliance For Tb Drug Development Inc
Global Alliance for TB Drug Development Inc, a not-for-profit organization, is dedicated to accelerating the discovery, development, and delivery of new, faster-acting, and affordable tuberculosis (TB) drugs for the global community. The alliance, uniquely positioned between the public, private, academic, and philanthropic sectors, leverages partnerships to most efficiently advance TB drug development. Their product development partnership (PDP) model combines the research and development expertise of their staff with the skills and resources of their partners, harnessing the most promising science from around the world. By minimizing costs and optimizing scientific capability, the alliance speeds up new TB drug development.
The organization's current projects include the evaluation of a novel and potentially shorter drug regimen, BPAMZ, for patients with drug-sensitive (DS) and drug-resistant (MDR) pulmonary tuberculosis. This regimen consists of four different antimicrobials: bedaquiline, pretomanid, moxifloxacin, and pyrazinamide. The drug regimen is administered for four months to patients with DS-TB and for six months to patients with MDR-TB or mono-resistance to rifampicin or isoniazid. Another project, the Zenix clinical trial, sought to optimize linezolid dosing as part of the BPAL regimen for extensively drug-resistant tuberculosis (XDR-TB) and those with pre-XDR-TB and multidrug-resistant TB whose prior treatment has failed or who have not tolerated their treatment. The top-line results of Zenix, presented at IAS 2021 and published in the New England Journal of Medicine, showed that the effectiveness of the BPAL regimen could be maintained with reduced dosing of linezolid. These results have been incorporated into the World Health Organization's guidelines for the treatment of drug-resistant TB, enabling a significantly broader patient population to be treated with BPAL-based regimens.
Impact
This information is meant to be a general summary of Global Alliance For Tb Drug Development Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Thursday, August 15, 2024
Global Alliance For Tb Drug Development Inc's impact lies in its dedication to accelerating the discovery and development of new drugs to facilitate the control of tuberculosis throughout the world and ensure accessibility to the global community. Through its research and development efforts, TB Alliance has made significant strides in advancing TB drug development.
One notable project, SimplicitB, is evaluating a novel and potentially shorter drug regimen for patients with drug-sensitive and drug-resistant pulmonary tuberculosis. This regimen, known as BPAMZ, has shown promise in treating both DS-TB and MDR-TB effectively.
Another initiative, Zenix, focused on optimizing the BPAL regimen to treat extensively drug-resistant tuberculosis, with promising results published in prestigious medical journals and incorporated into World Health Organization guidelines.
Furthermore, the LIFT-TB program aims to increase treatment completion rates for drug-resistant TB through the adoption and scaling up of new regimens, benefiting thousands of individuals in high-burden regions.
Overall, the Global Alliance For Tb Drug Development Inc's impact is evident in its innovative approaches to TB drug development, its collaborations with various partners, and its contribution to the global fight against tuberculosis.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Organization Details
Founding Year
2000
Phone
(212) 227-7540
Principal Officer
Angela Vanderploeg
Main Address
80 PINE STREET 20TH FLOOR, NEW YORK, NY, 10005
Website
www.tballiance.org
NTEE Category
Code: Q30 - International
If you are a representative of Global Alliance For Tb Drug Development Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.